CHL
MCID: LYM133
MIFTS: 72

Lymphoma, Hodgkin, Classic (CHL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lymphoma, Hodgkin, Classic

MalaCards integrated aliases for Lymphoma, Hodgkin, Classic:

Name: Lymphoma, Hodgkin, Classic 57 73 36 38
Hodgkin Lymphoma 57 11 19 58 75 12 41 14 31 33
Hodgkin Disease 57 11 19 73 53 71 33
Classic Hodgkin Lymphoma 58 28 5
Hodgkin's Lymphoma 11 19 14
Hodgkins Lymphoma 11 28 16
Chl 57 73
Hodgkin's Disease of Lymph Nodes of Inguinal Region and/or Lower Limb 71
Classical Hodgkin Lymphoma, Type Not Specified 33
Hodgkin's Disease of Intrapelvic Lymph Nodes 71
Stage Ii Subdiaphragmatic Hodgkin Lymphoma 11
Stage I Subdiaphragmatic Hodgkin Lymphoma 11
Lymphoma, Hodgkin, Susceptibility to 38
Hodgkin Lymphoma, Susceptibility to 57
Malignant Lymphogranulomatosis 33
Malignant Hodgkin Lymphoma 33
Malignant Lymphogranuloma 33
Classic Hodgkin Disease 58
Lymphoma, Hodgkin's 19
Hodgkin's Sarcoma 11
Hodgkin's Disease 75
Hl 11

Characteristics:


Inheritance:

Lymphoma, Hodgkin, Classic: Autosomal recessive 57
Hodgkin Lymphoma: Multigenic/multifactorial 58

Prevelance:

Classic Hodgkin Lymphoma: 1-9/100000 (Europe, France, United States, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-5/10000 (Europe, Europe) 58
Hodgkin Lymphoma: 1-9/100000 (Europe, United States) 1-5/10000 (Europe) 58

Age Of Onset:

Classic Hodgkin Lymphoma: All ages 58
Hodgkin Lymphoma: Adolescent,Adult,Childhood,Elderly,Infancy 58

Age Of Death:

Classic Hodgkin Lymphoma: any age 58

Classifications:

Orphanet: 58  
Rare haematological diseases


Summaries for Lymphoma, Hodgkin, Classic

MedlinePlus: 41 What is Hodgkin lymphoma? Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system. Your lymph system is part of your immune system. It helps protect your body from infection and disease. The lymph system is made up of tissues and organs that produce, store, and carry white blood cells. It includes your: Bone marrow Lymph nodes Lymphatic vessels Spleen Thymus Tonsils Hodgkin lymphoma is one of the main types of lymphoma. The other is non-Hodgkin lymphoma. Each type starts in different types of white blood cells. What causes Hodgkin lymphoma? The cause of Hodgkin lymphoma is unknown. But there are certain people who are at higher risk of developing it. Who is more likely to develop Hodgkin lymphoma? Certain factors can make you more likely to develop Hodgkin lymphoma: Age. Hodgkin lymphoma is most common in early adulthood (age 20-39 years) and in late adulthood (age 65 years and older). Being male. The risk of adult Hodgkin lymphoma is slightly higher in males than in females. Past Epstein-Barr virus (EBV) infection. Having an infection with EBV as a young child or teenager increases your risk of Hodgkin lymphoma. A family history of Hodgkin lymphoma. Having a parent or sibling with Hodgkin lymphoma increases your risk of developing it. What are the symptoms of Hodgkin lymphoma? The signs and symptoms of Hodgkin lymphoma may include: Painless, swollen lymph nodes in the neck, underarm, or groin Fever for no known reason Drenching night sweats (very heavy sweating during sleep) Weight loss for no known reason in the past 6 months Itchy skin, especially after bathing or drinking alcohol Fatigue How is Hodgkin lymphoma diagnosed? To find out if you have Hodgkin lymphoma, your provider: Will ask about your symptoms and medical history. This will include checking for signs of disease, such as lumps or anything else that seems unusual. May order some lab tests, such as: Complete blood count Blood chemistry studies Lactate dehydrogenase (LDH) test Erythrocyte sedimentation rate (ESR) test Blood tests to rule out other medical conditions May do imaging tests such as a CT and PET (positron emission tomography) scans May do a lymph node biopsy What are the treatments for Hodgkin lymphoma? Treatments for Hodgkin lymphoma include: Chemotherapy Radiation therapy Targeted therapy, which uses drugs or other substances that attack specific cancer cells with less harm to normal cells Cancer immunotherapy Hodgkin lymphoma can usually be cured if it is found and treated early. NIH: National Cancer Institute

MalaCards based summary: Lymphoma, Hodgkin, Classic, also known as hodgkin lymphoma, is related to mantle cell lymphoma and primary cutaneous t-cell non-hodgkin lymphoma. An important gene associated with Lymphoma, Hodgkin, Classic is KLHDC8B (Kelch Domain Containing 8B), and among its related pathways/superpathways are miRNAs involved in DNA damage response and ncRNAs involved in STAT3 signaling in hepatocellular carcinoma. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are fatigue and immunodeficiency

UniProtKB/Swiss-Prot: 73 A malignant disease characterized by progressive enlargement of the lymph nodes, spleen and general lymphoid tissue, and the presence of large, usually multinucleate, cells (Reed-Sternberg cells). Reed- Sternberg cells compose only 1-2% of the total tumor cell mass. The remainder is composed of a variety of reactive, mixed inflammatory cells consisting of lymphocytes, plasma cells, neutrophils, eosinophils and histiocytes.

Orphanet 58 Classic hodgkin lymphoma: Classical Hodgkin lymphoma (CHL) is a B-cell lymphoma characterized histologically by the presence of large mononuclear Hodgkin cells and multinucleated Reed-Sternberg (HRS) cells.

Hodgkin lymphoma: Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.

OMIM®: 57 Classic Hodgkin lymphoma is a lymph node cancer of germinal center B-cell origin. Hodgkin lymphoma tumors consist of a minority of malignant cells, known as 'Reed-Sternberg' (RS) cells, mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of 2 nuclei (summary by Salipante et al., 2009). (236000) (Updated 24-Oct-2022)

GARD: 19 Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases.

Disease Ontology: 11 A lymphoma that is marked by the presence of a type of cell called the Reed-Sternberg cell.

Wikipedia: 75 Hodgkin lymphoma (HL) is a type of lymphoma, in which cancer originates from a specific type of white... more...

Related Diseases for Lymphoma, Hodgkin, Classic

Diseases related to Lymphoma, Hodgkin, Classic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2258)
# Related Disease Score Top Affiliating Genes
1 mantle cell lymphoma 33.0 TP53 TNFRSF8 PAX5 MIR155 IRF4 ALK
2 primary cutaneous t-cell non-hodgkin lymphoma 32.9 TNFRSF8 MIR21 MIR155
3 lymphoma, mucosa-associated lymphoid type 32.9 TP53 TNFRSF8 PAX5 MIR155 IRF4
4 plasmablastic lymphoma 32.7 TNFRSF8 PAX5 IRF4
5 mature t-cell and nk-cell lymphoma 32.6 TP53 TNFRSF8 PAX5 MIR21 MIR155 ALK
6 mediastinal gray zone lymphoma 32.5 TNFRSF8 PAX5
7 hodgkin's lymphoma, nodular sclerosis 32.4 TNFRSF8 PAX5 KLHDC8B
8 hodgkin's lymphoma, lymphocytic depletion 32.3 TNFRSF8 PAX5
9 hepatosplenic t-cell lymphoma 32.3 TNFRSF8 ALK
10 gray zone lymphoma 32.3 TNFRSF8 PAX5 IRF4
11 marginal zone b-cell lymphoma 32.0 TP53 TNFRSF8 PAX5 IRF4
12 chronic lymphocytic leukemia/small lymphocytic lymphoma 31.9 TP53 TNFRSF8 PAX5
13 primary mediastinal b-cell lymphoma 31.8 TNFRSF8 MIR155 IRF4
14 peripheral t-cell lymphoma 31.8 TP53 TNFRSF8 PAX5 MIR21 MIR155 ALK
15 peripheral nervous system disease 31.7 TP53 TNFRSF8 MIR30B MIR30A MIR21 MIR140
16 central nervous system lymphoma 31.5 TNFRSF8 PAX5 MIR18A IRF4
17 bone lymphoma 31.5 TNFRSF8 PAX5 IRF4 ALK
18 breast lymphoma 31.5 TNFRSF8 PAX5 IRF4 ALK
19 skin carcinoma 31.4 TP53 MIR30A MIR21 MIR18A MIR140
20 cardiovascular system disease 31.3 MIR30B MIR30A MIR21 MIR155 MIR140
21 respiratory failure 31.2 MIR30B MIR21 MIR155 CSF3
22 dermatomyositis 31.2 MIR30A MIR21 MIR155
23 adult lymphoma 31.2 TNFRSF8 PAX5 IRF4 ALK
24 childhood lymphoma 31.2 TNFRSF8 PAX5 IRF4 ALK
25 testicular lymphoma 31.1 TNFRSF8 IRF4
26 brain cancer 31.1 TP53 MIR30A MIR21 MIR20A MIR155 MIR140
27 lymphatic system disease 31.1 TP53 TNFRSF8 MIR30A MIR21 MIR20A MIR18A
28 sezary's disease 31.1 TP53 TNFRSF8 MIR155 IRF4 ALK
29 skin melanoma 31.0 TP53 MIR21 MIR200A
30 plasma cell neoplasm 31.0 TP53 PVT1 PAX5 MIR155 MIR140
31 multicentric castleman disease 31.0 TNFRSF8 PAX5 IRF4 ALK
32 arteries, anomalies of 31.0 MIR30B MIR30A MIR21 MIR20A MIR18A MIR155
33 polymyositis 31.0 MIR30A MIR21 MIR155
34 esophageal cancer 31.0 TP53 PVT1 MIR30A MIR21 MIR20A MIR200A
35 immune deficiency disease 30.9 TNFRSF8 MIR30A MIR21 MIR20A MIR155 MIR140
36 interstitial lung disease 30.9 MIR30B MIR30A MIR21 MIR155
37 head and neck cancer 30.9 TP53 MIR30A MIR21 MIR20A MIR200A MIR18A
38 body mass index quantitative trait locus 11 30.9 TP53 MIR30A MIR21 MIR20A MIR18A MIR155
39 central nervous system disease 30.9 MIR30B MIR30A MIR21 MIR20A MIR200A MIR18A
40 leukemia, acute myeloid 30.9 TP53 TNFRSF8 PAX5 MIR374A MIR30A MIR21
41 lung cancer susceptibility 3 30.9 TP53 MIR30A MIR21 MIR200A MIR140 ALK
42 plasmacytoma 30.9 PVT1 PAX5 IRF4
43 hepatocellular carcinoma 30.9 TP53 PVT1 MIR374A MIR30A MIR21 MIR20A
44 lung lymphoma 30.8 TNFRSF8 PAX5 IRF4
45 burkitt lymphoma 30.8 TP53 TNFRSF8 PVT1 PAX5 MIR21 MIR155
46 thyroid gland anaplastic carcinoma 30.8 TP53 MIR30A MIR200A MIR18A ALK
47 bone cancer 30.8 TP53 MIR30A MIR21 MIR186 MIR155 MIR140
48 nervous system disease 30.8 TP53 MIR374A MIR30B MIR30A MIR21 MIR20A
49 interstitial lung disease 2 30.8 TP53 MIR30B MIR30A MIR21 MIR140
50 type 2 diabetes mellitus 30.8 TP53 PVT1 MIR30B MIR30A MIR21 MIR20A

Graphical network of the top 20 diseases related to Lymphoma, Hodgkin, Classic:



Diseases related to Lymphoma, Hodgkin, Classic

Symptoms & Phenotypes for Lymphoma, Hodgkin, Classic

Human phenotypes related to Lymphoma, Hodgkin, Classic:

58 30 (show all 31)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
HP:0012378
2 immunodeficiency 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002721
3 cellular immunodeficiency 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0005374
4 lymphoma 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
HP:0002665
5 lymphadenopathy 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
HP:0002716
6 hyperhidrosis 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
HP:0000975
7 fever 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
HP:0001945
8 anorexia 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
HP:0002039
9 cough 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
HP:0012735
10 chest pain 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
HP:0100749
11 weight loss 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
HP:0001824
12 pruritus 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
HP:0000989
13 poor appetite 58 30 Frequent (33%) Frequent (79-30%)
HP:0004396
14 ataxia 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
HP:0001251
15 respiratory insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002093
16 splenomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
HP:0001744
17 hepatomegaly 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
HP:0002240
18 dyspnea 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002094
19 hemoptysis 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
HP:0002105
20 peripheral neuropathy 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
HP:0009830
21 migraine 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002076
22 skin rash 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000988
23 headache 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002315
24 bone pain 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
HP:0002653
25 osteolysis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002797
26 bone marrow hypocellularity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0005528
27 hodgkin lymphoma 30 Very rare (1%) HP:0012189
28 neoplasm 58 Occasional (29-5%)
Occasional (29-5%)
29 abnormality of blood and blood-forming tissues 58 Occasional (29-5%)
30 polyclonal elevation of igm 30 HP:0003459
31 impaired lymphocyte transformation with phytohemagglutinin 30 HP:0003347

Symptoms via clinical synopsis from OMIM®:

57 (Updated 24-Oct-2022)
Lab:
polyclonal elevation of igm
impaired lymphocyte transformation with phytohemagglutinin

Heme:
hodgkin disease

Clinical features from OMIM®:

236000 (Updated 24-Oct-2022)

Drugs & Therapeutics for Lymphoma, Hodgkin, Classic

Drugs for Lymphoma, Hodgkin, Classic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 583)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Nitric Oxide Approved Phase 4 10102-43-9 145068
5
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
6
Prilocaine Approved Phase 4 721-50-6 4906
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
9
Idarubicin Approved Phase 4 58957-92-9 42890
10
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
11
Pirarubicin Investigational Phase 4 72496-41-4 4844
12
Tenofovir Experimental, Investigational Phase 4 147127-20-6, 202138-50-9 464205 6398764
13
Dexchlorpheniramine Experimental, Investigational Phase 4 25523-97-1 33036
14 Reverse Transcriptase Inhibitors Phase 4
15 Antifungal Agents Phase 4
16 Angiotensin Receptor Antagonists Phase 4
17 Angiotensin II Type 1 Receptor Blockers Phase 4
18 Giapreza Phase 4
19 Anti-Arrhythmia Agents Phase 4
20 Lidocaine, Prilocaine Drug Combination Phase 4
21 Sodium Channel Blockers Phase 4
22 Anesthetics, Inhalation Phase 4
23 Anesthetics, General Phase 4
24 Diuretics, Potassium Sparing Phase 4
25 Antioxidants Phase 4
26 Radiation-Protective Agents Phase 4
27 Platelet Aggregation Inhibitors Phase 4
28 Phosphodiesterase Inhibitors Phase 4
29 Hematinics Phase 4
30 Chrysarobin Phase 4
31
Epoetin Alfa Phase 4
32
Tioguanine Approved Phase 3 154-42-7 2723601
33
Enalaprilat Approved Phase 3 76420-72-9 6917719 5462501
34
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5388962 5362032
35
Clarithromycin Approved Phase 3 81103-11-9 84029
36
Metronidazole Approved Phase 3 443-48-1, 69198-10-3 4173
37
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
38
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
39
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
40
Etoposide Approved Phase 3 33419-42-0 36462
41
Aldesleukin Approved Phase 2, Phase 3 110942-02-4
42
Dexrazoxane Approved, Withdrawn Phase 3 24584-09-6 71384
43
Erythromycin Approved, Investigational, Vet_approved Phase 3 55-31-2, 114-07-8 12560
44
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
45
Zoledronic acid Approved Phase 3 118072-93-8 68740
46
Mercaptopurine Approved Phase 3 50-44-2 667490
47
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
48
Calcium carbonate Approved, Investigational Phase 3 471-34-1
49
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 11947679 6857599
50
Decitabine Approved, Investigational Phase 2, Phase 3 2353-33-5 451668

Interventional clinical trials:

(show top 50) (show all 2479)
# Name Status NCT ID Phase Drugs
1 An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma Unknown status NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
2 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
3 Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Unknown status NCT04134247 Phase 4 PD-1 combined with chemotherapy;chemotherapy
4 Optimization of the Primary Therapy for Patients With Hodgkin's Lymphoma and Evaluation of the Positron Emission Tomography (PET) as a Diagnostic Tool for Primary Staging and Assessment of the Effects of the Therapy Unknown status NCT00188149 Phase 4 Combined chemotherapy (ABVD, BACOPP-D)
5 Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma Unknown status NCT02526823 Phase 4 R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
6 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
7 A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy Unknown status NCT02585947 Phase 4 Tenofovir
8 Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma Completed NCT01124526 Phase 4 Rituximab Fludarabine Cyclophosphamide
9 A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy Completed NCT01990534 Phase 4 Brentuximab Vedotin
10 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
11 Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture Completed NCT00808171 Phase 4 Livopan;EMLA
12 A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg Completed NCT01164475 Phase 4 Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
13 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
14 Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma Completed NCT00168727 Phase 4 ibritumomab tiuxetan (Zevalin®)
15 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
16 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
17 The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP Completed NCT00162955 Phase 4 Valsartan
18 A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy. Completed NCT00430352 Phase 4 rituximab [MabThera/Rituxan]
19 Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial Completed NCT00926757 Phase 4 Entecavir prophylaxis;Therapeutic entecavir
20 A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA Completed NCT01180049 Phase 4 temsirolimus
21 A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens Completed NCT00090038 Phase 4 rituximab
22 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
23 A Prospective Multi-center Study for the Treatment of Chinese Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma Using a Modified COG Strategy Recruiting NCT04726501 Phase 4
24 Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. Recruiting NCT03500133 Phase 4 Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.;Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.;Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.;Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.;High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.;Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
25 Enhancing Effect on Tumour Apoptosis With the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients With Hodgkin´s Lymphoma Recruiting NCT05490953 Phase 4 Pentoxifylline;Placebo
26 B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021) Recruiting NCT05518383 Phase 4 Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
27 Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study - Intervention Pilot Study Recruiting NCT05191225 Phase 4 RiTUXimab Injection [Truxima]
28 First International Inter-Group Study for Nodular Lymphocyte-Predominant Hodgkin's Lymphoma in Children and Adolescents Active, not recruiting NCT01088750 Phase 4 cyclophosphamide;prednisolone;vinblastine sulfate
29 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
30 Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial Unknown status NCT01516580 Phase 3 Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
31 The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood Unknown status NCT00003728 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
32 Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients Unknown status NCT01277172 Phase 2, Phase 3
33 A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma Unknown status NCT01570049 Phase 3 Bendamustine
34 Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity Unknown status NCT03265574 Phase 3 Enalapril
35 Phase III Randomized, Multi-center Study to Evaluate the Effect of R-mabHDI in Patients With Lymphocytic Predominant Hodgkin's Lymphoma Unknown status NCT00816959 Phase 3 R-mabHDI and ABVD;ABVD
36 Minimal Initial Therapy (MIT) for "Early" Supradiaphragmatic Hodgkin's Disease: A Multicenter Randomized Trial of Short Neoadjuvant Chemotherapy (VAPEC-B) Plus Involved Field Radiotherapy (MIT) Versus Mantle Radiotherapy Unknown status NCT00002987 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisolone;vincristine sulfate
37 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
38 Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Unknown status NCT02722733 Phase 3 G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
39 Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study) Unknown status NCT00154440 Phase 3 proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
40 A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma Unknown status NCT00078598 Phase 3 Rituximab or Iodine I 131 Tositumomab Therapy
41 A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab) Unknown status NCT00022685 Phase 3
42 A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
43 Non-Hodgkin's Lymphoma T Cell Protocol Unknown status NCT00003423 Phase 3 asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
44 A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma Unknown status NCT00017290 Phase 3 cyclophosphamide;prednisone;vincristine sulfate
45 Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction Unknown status NCT00003639 Phase 3 chlorambucil;dexamethasone;idarubicin
46 A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Unknown status NCT02186574 Phase 3 Tenofovir disoproxil;Placebo Oral Tablet
47 A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups Unknown status NCT00003815 Phase 3 carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
48 The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
49 The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
50 Combination Chemotherapy Using Cisplatin, Gemcitabine, Ifosfamide, Etoposide, L-asparaginase and Dexamethasone (SIMPLE) for Newly Diagnosed and Relapsed/Refractory NK/T Cell Malignancies Unknown status NCT03623087 Phase 3 Cisplatin;Gemcitabine;Etoposide (VP-16);Dexamethasone;L-asparaginase

Search NIH Clinical Center for Lymphoma, Hodgkin, Classic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine
Chlorambucil
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Dacarbazine
Ifosfamide
Lomustine
Mechlorethamine
Mechlorethamine hydrochloride
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
sargramostim
Vinblastine
Vinblastine Sulfate
Vincristine
Vincristine Sulfate
vinorelbine
Vinorelbine tartrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphoma, Hodgkin, Classic cell therapies at LifeMap Discovery.

Genetic Tests for Lymphoma, Hodgkin, Classic

Genetic tests related to Lymphoma, Hodgkin, Classic:

# Genetic test Affiliating Genes
1 Classic Hodgkin Lymphoma 28 KLHDC8B
2 Hodgkins Lymphoma 28

Anatomical Context for Lymphoma, Hodgkin, Classic

Organs/tissues related to Lymphoma, Hodgkin, Classic:

MalaCards : Bone Marrow, Lymph Node, T Cells, Bone, Thymus, Spleen, B Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Hodgkin, Classic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Lymphoma, Hodgkin, Classic

Articles related to Lymphoma, Hodgkin, Classic:

(show top 50) (show all 59751)
# Title Authors PMID Year
1
Mutations in a gene encoding a midbody kelch protein in familial and sporadic classical Hodgkin lymphoma lead to binucleated cells. 62 57 5
19706467 2009
2
Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. 53 62 57
20436485 2010
3
High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. 53 62 57
17539776 2007
4
Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. 53 62 57
11830502 2002
5
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. 62 57
21368758 2011
6
A genome screen of families at high risk for Hodgkin lymphoma: evidence for a susceptibility gene on chromosome 4. 62 57
15994882 2005
7
Characteristics of Hodgkin's lymphoma after infectious mononucleosis. 62 57
14523140 2003
8
Combined segregation and linkage analysis of 59 Hodgkin's disease families indicates the role of HLA determinants. 62 57
10878668 2000
9
A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden. 62 57
10914686 2000
10
Familial Hodgkin's disease: a disease of young adulthood? 62 57
9111426 1997
11
Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. 62 57
7824015 1995
12
Localization of predisposition to Hodgkin disease in the HLA class II region. 62 57
8116619 1994
13
Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. 62 57
8381153 1993
14
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. 62 57
1671232 1991
15
Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. 62 57
2172169 1990
16
Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. 62 57
2537928 1989
17
Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. 62 57
2536894 1989
18
Epstein-Barr viral DNA in tissues of Hodgkin's disease. 62 57
2821817 1987
19
HLA in familial Hodgkin's disease. 62 57
6875280 1983
20
Simultaneous Hodgkin's disease in three siblings with identical HLA-genotype. 62 57
7397649 1980
21
Infectious mononucleosis and Hodgkin's disease. 62 57
681023 1978
22
Serum genetic markers in a Newfoundland isolate with a familial aggregate of Hodgkin's disease. 62 57
680699 1978
23
HLA in familial Hodgkin's disease. Results and a new hypothesis;. 62 57
844915 1977
24
Hodgkin's disease in siblings. 62 57
831107 1977
25
Familial Hodgkin's disease and the major histocompatibility complex. 62 57
144365 1977
26
Familial Hodgkin's disease and associated cancer. A clinical-pathologic study. 62 57
991117 1976
27
Varied manifestations of a familial lymphoproliferative disorder. 62 57
806230 1975
28
Familial Hodgkin's disease: an environmental and genetic disorder. 62 57
4137662 1974
29
Family studies in Hodgkin's disease. 62 57
4842358 1974
30
Familial Hodgkin's disease. 62 57
4115609 1972
31
Mortality from Hodgkin's disease in the United States. Evidence for the multiple-aetiology hypothesis. 62 57
4177934 1968
32
Epidemiology of Hodgkin's disease. 62 57
5329907 1966
33
[FAMILIAL HODGKIN'S DISEASE]. 62 57
14154061 1964
34
Subtype distribution of lymphomas in northwestern Iran: a retrospective analysis of 659 cases according to World Health Organization classification. 62 41
36224530 2022
35
Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis. 62 41
36181035 2022
36
Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma. 62 41
36135049 2022
37
Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77+ B-cells reveals a distinct subset of differentially expressed miRNAs. 62 46
19775296 2009
38
Infection and lymphoma. 57
14523136 2003
39
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. 53 62
20527019 2010
40
Common misdiagnoses in lymphomas and avoidance strategies. 53 62
20227918 2010
41
B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. 53 62
20398809 2010
42
The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. 53 62
20065852 2010
43
PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus. 53 62
20118907 2010
44
IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma. 53 62
19804451 2010
45
Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236. 53 62
19931589 2010
46
Connective tissue growth factor is expressed in malignant cells of Hodgkin lymphoma but not in other mature B-cell lymphomas. 53 62
20093237 2010
47
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. 53 62
20093413 2010
48
IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. 53 62
19821826 2010
49
Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma. 53 62
19550297 2010
50
TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. 53 62
19890373 2010

Variations for Lymphoma, Hodgkin, Classic

ClinVar genetic disease variations for Lymphoma, Hodgkin, Classic:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TP53 NM_000546.6(TP53):c.1118del (p.Lys373fs) DEL Pathogenic
1052297 GRCh37: 17:7572991-7572991
GRCh38: 17:7669673-7669673
2 KLHDC8B NM_173546.3(KLHDC8B):c.-158C>T SNV Pathogenic
273 rs387906223 GRCh37: 3:49209095-49209095
GRCh38: 3:49171662-49171662
3 MYC NM_002467.6(MYC):c.77A>G (p.Asn26Ser) SNV Uncertain Significance
1679939 GRCh37: 8:128750540-128750540
GRCh38: 8:127738294-127738294
4 MET NM_000245.4(MET):c.2975C>T (p.Thr992Ile) SNV Uncertain Significance
41624 rs56391007 GRCh37: 7:116411990-116411990
GRCh38: 7:116771936-116771936
5 KRAS NM_004985.5(KRAS):c.436G>A (p.Ala146Thr) SNV Uncertain Significance
197243 rs121913527 GRCh37: 12:25378562-25378562
GRCh38: 12:25225628-25225628
6 FGFR3 NM_000142.5(FGFR3):c.1181C>T (p.Thr394Met) SNV Uncertain Significance
576979 rs747694886 GRCh37: 4:1806162-1806162
GRCh38: 4:1804435-1804435
7 FGFR4 NM_213647.3(FGFR4):c.407C>T (p.Pro136Leu) SNV Likely Benign
1679938 GRCh37: 5:176517797-176517797
GRCh38: 5:177090796-177090796

Copy number variations for Lymphoma, Hodgkin, Classic from CNVD:

6 (show top 50) (show all 204)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 15434 1 115570986 115748025 Copy number Hodgkin''s lymphoma
2 18148 1 144224941 245407169 Copy number Hodgkin''s lymphoma
3 21362 1 158258490 227249364 Copy number Hodgkin''s lymphoma
4 29781 1 235850830 237390561 Copy number Hodgkin''s lymphoma
5 29922 1 238038528 245407169 Copy number Hodgkin''s lymphoma
6 35390 1 6293700 18251002 Copy number Hodgkin''s lymphoma
7 37216 1 87388008 120033702 Copy number Hodgkin''s lymphoma
8 37460 1 9146813 16679690 Copy number Hodgkin''s lymphoma
9 38491 10 102895110 124244273 Copy number Hodgkin''s lymphoma
10 40197 10 125057756 126954997 Copy number Hodgkin''s lymphoma
11 40637 10 131215760 132635356 Copy number Hodgkin''s lymphoma
12 41620 10 214400 133778456 Copy number Hodgkin''s lymphoma
13 41883 10 25240974 36004765 Copy number Hodgkin''s lymphoma
14 43571 10 46999355 135111152 Copy number Hodgkin''s lymphoma
15 43572 10 46999355 48101366 Copy number Hodgkin''s lymphoma
16 43573 10 46999355 49467140 Copy number Hodgkin''s lymphoma
17 44594 10 60095355 78914295 Copy number Hodgkin''s lymphoma
18 44784 10 6277674 8346525 Copy number Hodgkin''s lymphoma
19 45116 10 67551761 78914295 Copy number Hodgkin''s lymphoma
20 46267 10 79687952 85721525 Copy number Hodgkin''s lymphoma
21 46788 10 86278375 101096913 Copy number Hodgkin''s lymphoma
22 49260 11 104569097 133732868 Copy number Hodgkin''s lymphoma
23 50177 11 115327798 134437143 Copy number Hodgkin''s lymphoma
24 52493 11 178227 35140556 Copy number Hodgkin''s lymphoma
25 57515 11 63560139 72573784 Copy number Hodgkin''s lymphoma
26 57783 11 64800000 75000000 Gain Hodgkin''s lymphoma
27 58506 11 68129639 134437143 Copy number Hodgkin''s lymphoma
28 60254 11 84447402 105734987 Copy number Hodgkin''s lymphoma
29 60677 11 89286313 104569095 Copy number Hodgkin''s lymphoma
30 64335 12 126737931 132373208 Copy number Hodgkin''s lymphoma
31 65226 12 152534 16164790 Copy number Hodgkin''s lymphoma
32 65227 12 152534 525774777 Copy number Hodgkin''s lymphoma
33 67817 12 4490384 44739500 Copy number Hodgkin''s lymphoma
34 67821 12 45000000 56400000 Gain Hodgkin''s lymphoma
35 68783 12 51500000 63100000 Gain Hodgkin''s lymphoma
36 68979 12 52417126 60370345 Copy number Hodgkin''s lymphoma
37 69531 12 55627899 56288135 Copy number Hodgkin''s lymphoma
38 70095 12 58245748 132373208 Copy number Hodgkin''s lymphoma
39 70715 12 64263728 66931770 Copy number Hodgkin''s lymphoma
40 71442 12 70000000 82000000 Gain Hodgkin''s lymphoma
41 72563 12 82669309 120958351 Copy number Hodgkin''s lymphoma
42 75245 13 18397782 106691271 Copy number Hodgkin''s lymphoma
43 75246 13 18397782 114117460 Copy number Hodgkin''s lymphoma
44 75871 13 25400000 38500000 Loss Hodgkin''s lymphoma
45 75878 13 25500000 32200000 Loss Hodgkin''s lymphoma
46 79388 13 71000000 83000000 Loss Hodgkin''s lymphoma
47 83222 14 19570807 42171562 Copy number Hodgkin''s lymphoma
48 83386 14 20383489 53262838 Copy number Hodgkin''s lymphoma
49 83387 14 20383489 56623380 Copy number Hodgkin''s lymphoma
50 85558 14 48879628 106278173 Copy number Hodgkin''s lymphoma

Expression for Lymphoma, Hodgkin, Classic

Search GEO for disease gene expression data for Lymphoma, Hodgkin, Classic.

Pathways for Lymphoma, Hodgkin, Classic

Pathways related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.75 TP53 MIR21 MIR20A MIR18A
2 10.21 MIR21 MIR200A

GO Terms for Lymphoma, Hodgkin, Classic

Cellular components related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.58 MIR30B MIR30A MIR21 MIR20A MIR200A MIR18A
2 extracellular vesicle GO:1903561 9.26 MIR30B MIR30A MIR21 MIR20A

Biological processes related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.72 MIR21 MIR20A MIR140 CSF3
2 miRNA-mediated gene silencing GO:0035195 9.64 MIR520A MIR374A MIR30B MIR30A MIR21 MIR20A
3 negative regulation of gene expression GO:0010629 9.43 TP53 MIR21 MIR20A MIR186 MIR155 MIR140
4 negative regulation of regulatory T cell differentiation GO:0045590 9.26 MIR30B MIR21
5 positive regulation of vascular associated smooth muscle cell differentiation involved in phenotypic switching GO:1905932 9.16 MIR18A MIR140

Molecular functions related to Lymphoma, Hodgkin, Classic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.61 TP53 MIR374A MIR30A MIR21 MIR20A MIR186
2 mRNA base-pairing translational repressor activity GO:1903231 9.36 MIR520A MIR374A MIR30B MIR30A MIR21 MIR20A

Sources for Lymphoma, Hodgkin, Classic

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....